Sildenafil citrate linked to increased chorodial thickness

Article

phosphodiesterase-5 inhibitor, sildenafil citrate, increases chorodial thickness ? an associated risk factor for central serous chorioretinopathy

A study published in Retina shows the phosphodiesterase-5 inhibitor, sildenafil citrate, increases chorodial thickness – an associated risk factor for central serous chorioretinopathy.

Dr Susham K. Vance et al., LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, USA, conducted a prospective, interventional study involving the administration of 100 mg of sildenafil citrate to 8 subjects with no previous ocular history. Enhanced depth imaging spectral-domain optical coherence tomography was used to measure choroidal thickness in both eyes at 1-hour and 3-hour intervals after ingestion.

The findings demonstrated that the mean chorodial thickness had increased by 12.3% from 334 μm to 375 μm after 1-hour. The mean choroidal thickness was 11.6% thicker than baseline at the 3-hour interval. No significant changes were noted in choroidal thickness between the 1-hour and 3-hour intervals.

The results were related to previous studies of phosphodiesterase-5 inhibitors and central serous chorioretinopathy. Sildenafil citrate increases choroidal thickness both 1-hour and 3-hours after administration.

Related Videos
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network
Baruch Kuppermann, MD, PhD
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns."
© 2024 MJH Life Sciences

All rights reserved.